Repligen Cp: (NASD: RGEN)
$8.23
-0.38 (-4.41%)
Volume 723,233
May 22 04:00 PM ET
Zacks Rank: NA 
| |
Overview Quote
Stock Activity
| Day Low - High | 8.00 - 8.86 |
| 52wk Low - High | 3.72 - 9.65 |
| Previous Close | 8.61 |
| Avg. Volume | 378,744 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 268.80 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.89 |
| PE (Forward) | 0.00 |
| Current Year Est. | 0.00 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
|
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
96 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | NA |
| Current Quarter Estimate | NA |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 08-08-2013 |
| EPS Last Year | 0.50 |
| Expected Earnings Growth | NA |
Company Description
Repligen Corporation develops new drugs based on naturally occurring peptides and proteins for autism, organ transplantation and immune system diseases. The company's lead therapeutic products are secretin for autism and CTLA4-Ig for organ transplantation and autoimmune diseases. The company manufactures and markets products based on Protein A for the purification of antibodies, and it owns commercial rights to products based on synthetic forms of secretin for the diagnosis of pancreatic function.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (ND) |
Next Qtr (ND) |
Current Year (ND) |
Next Year (ND) |
|
|---|---|---|---|---|
| Average Estimate | NA | NA | NA | NA |
| Number of Estimates | NA | NA | NA | NA |
| Low Estimate | NA | NA | NA | NA |
| High Estimate | NA | NA | NA | NA |
| Year Ago EPS | NA | NA | NA | NA |
| EPS Growth | NA | NA | NA | NA |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| AETERNA ZENTARS | AEZS | 2.08 | |
|
| ANIKA THERAPEUT | ANIK | 14.45 | |
|
| GENTIUM SPA-ADR | GENT | 8.90 | |
|
| AASTROM BIOSCI | ASTM | 0.57 | |
|
| ACADIA PHARMA | ACAD | 13.79 | |
|
| ACHILLION PHARM | ACHN | 7.75 | |
|
| ADDEX THERA LTD | ADDXF | 6.94 | |
|
| AFFYMAX INC | AFFY | 1.45 | |
|
| ALEXION PHARMA | ALXN | 102.67 | |
|
| ALKERMES INC | ALKS | 31.98 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
Isis Pharma's ISIS-SMNRx Progresses
Apr 24, 2013
Positive Results on MDCO's Cangrelor
Jan 10, 2013
Optimer's Dificid Sales Look Good
Jan 09, 2013
Abbott's ABSORB in Phase III Trial
Jan 09, 2013
Repligen, Pfizer Collaborate
Jan 08, 2013
Aegerion Upbeat About 2013
Jan 08, 2013
Pipeline Update from Alnylam
Jan 08, 2013
Encouraging Prelim Results at DNDN
Jan 08, 2013
Financials
| EPS TTM | 0.50 |
| Sales | 62 |
| Net Income | 15 |
| Price/Earnings | 17.22 |
| Price/Book | 3.08 |
| Price/Cash Flow | 15.01 |
| Price/Sales | 4.08 |
News
Shares of Repligen Receive a Boost, Up 2.7% - Financial News Network Online - Market Movers
May 22, 2013
Repligen Earnings Review: 18 Days after Announcement Shares Up 0.6% (RGEN) - Comtex Smartrend(R)
May 20, 2013
Repligen Has Returned 71.8% Since SmarTrend Recommendation (RGEN) - Comtex Smartrend(R)
May 20, 2013
Earnings Look Back: Repligen Is Up 0.6% Since Reporting Quarterly Results 2 Weeks Ago (RGEN) - Financial News Network Online - Earnings Lookback
May 18, 2013
Repligen Shares Sinking Lower, Down 1.2% - Financial News Network Online - Market Movers
May 16, 2013
Repligen reports higher Q1 net income, provides outlook for 2013 - Datamonitor
May 16, 2013
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (ARNA, RGEN, ALNY, EXAS, ARIA) - Financial News Network Online - News Corner
May 10, 2013
Best Relative Performance in the Biotechnology Industry Detected in Shares of Arena Pharmaceuticals (ARNA, RGEN, ALNY, EXAS, ARIA) - Financial News Network Online - News Corner
May 9, 2013
Broker Recommendations
| Current ABR | 1.00 |
| ABR (Last Week) | NA |
| # of recs in ABR | 1 |
| Average Target Price | 10.00 |
| Industry Rank by ABR | 96 out of 265 |
| Rank in Industry | NA |
